Eyewash compositions

Abstract

To provide an eyewash composition that suppresses color fading of at least one selected from the group consisting of flavin adenine dinucleotide and a salt thereof.SOLUTION: The eyewash composition contains at least one selected from the group consisting of flavin adenine dinucleotide and a salt thereof, and epsilon-aminocaproic acid, but does not contain any antiseptic agents selected from quaternary ammonium salt-based antiseptic agents, p-hydroxybenzoic acid esters, chlorobutanol, and sorbic acid.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to an eyewash composition. [Background technology]

[0002] Conventionally, methods of washing eyes using an eyewash cup (eyecup) and methods of washing eyes by eye drops have been known. One example of an eyewash method using an eyewash cup is to pour an appropriate amount of eyewash solution (for example, about 5 mL) into the eyewash cup, then press the cup against the area around one eye to bring the eyewash solution in the cup into contact with the eye, and then blink several times to wash the eye. One example of an eyewash method by eye drops is to wash the eye by directly dropping the eyewash solution into the eye (for example, Patent Document 1).

[0003] On the other hand, flavin adenine dinucleotide and its salts are known as a type of component that has corneal repair activity, etc., and are yellow to pale yellowish brown in color. However, when these components are incorporated into eyewash solutions, there is a problem of discoloration due to exposure to light. Eyewashing methods using an eyewash cup require a larger amount of eyewash solution than eyewashing methods using eyedrops, and therefore the eyewash solution is often contained in a container with a relatively large capacity, resulting in a larger surface area of ​​the eyewash solution exposed to light. Furthermore, eyewashing methods using eyedrops have the advantages of not requiring an eyewash cup, being highly portable, and being easy to use on the go. However, these methods are often used on the go, and therefore the time of exposure to light is longer. For this reason, when flavin adenine dinucleotide or its salts are incorporated into eyewash solutions, there is a problem of their susceptibility to discoloration.

[0004] It is known that such discoloration can be suppressed by the use of a parahydroxybenzoic acid ester in combination. However, the incorporation of such a preservative tends to be undesirable in terms of its effect on the cornea and its adsorption to contact lenses. Therefore, there is a need for an eyewash composition that is excellent in suppressing the discoloration of flavin adenine dinucleotide and its salts without the incorporation of a preservative such as a parahydroxybenzoic acid ester. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] Japanese Patent Application Publication No. 2019-210265 Summary of the Invention [Problem to be solved by the invention]

[0006] Therefore, an object of the present disclosure is to provide an eyewash composition in which discoloration of flavin adenine dinucleotide and / or a salt thereof is suppressed. [Means for solving the problem]

[0007] The present inventors have conducted extensive research in light of the above-mentioned problems and have found that by incorporating epsilon aminocaproic acid into an eyewash composition containing flavin adenine dinucleotide and / or a salt thereof, fading of the flavin adenine dinucleotide and / or a salt thereof can be suppressed. The present invention was completed through further research based on this finding. That is, the present disclosure encompasses the following inventions. Item 1. An eyewash composition containing at least one selected from the group consisting of flavin adenine dinucleotide and salts thereof and epsilon aminocaproic acid, and not containing a preservative selected from the group consisting of quaternary ammonium salt-based preservatives, parahydroxybenzoic acid esters, chlorobutanol, and sorbic acids. Item 2. The eyewash composition according to Item 1, further comprising cyanocobalamin. Item 3. The eyewash composition according to Item 1 or 2, which is used for eyewashing using an eyewash cup or for eyewashing by eye drops. [Effects of the Invention]

[0008] By incorporating epsilon aminocaproic acid into an eyewash composition containing flavin adenine dinucleotide and / or a salt thereof, discoloration of the flavin adenine dinucleotide and / or a salt thereof can be suppressed. DETAILED DESCRIPTION OF THE INVENTION

[0009] The embodiments included in the present disclosure are described in further detail below.

[0010] The eyewash composition encompassed by the present disclosure contains at least one selected from the group consisting of flavin adenine dinucleotide and its salts and epsilon aminocaproic acid, and does not contain a preservative selected from quaternary ammonium salt-based preservatives, parahydroxybenzoic acid esters, chlorobutanol, and sorbic acids.

[0011] Flavin adenine dinucleotide and its salts are not limited as long as they are acceptable for use in eye drops and eye washes. Flavin adenine dinucleotide is known as a type of vitamin B2. Examples of flavin adenine dinucleotide salts include alkali metal salts (sodium salt, potassium salt, etc.) and alkaline earth metal salts (calcium salt, magnesium salt, etc.). These may be used alone or in combination of two or more. The content of at least one selected from the group consisting of flavin adenine dinucleotide and its salts in the eye wash composition is not limited as long as the effects of the present disclosure are obtained, but the total amount is preferably 0.0001 to 0.01 w / v%, more preferably 0.0005 to 0.005 w / v%, and even more preferably 0.003 to 0.005 w / v%.

[0012] Epsilon aminocaproic acid has been known as an anti-inflammatory agent. The content of epsilon aminocaproic acid in the eyewash composition is not limited as long as the effects of the present disclosure are obtained. However, from the viewpoint of further suppressing discoloration of the composition, the content in the eyewash composition is preferably 0.01 to 0.5 w / v%, more preferably 0.05 to 0.5 w / v%, even more preferably 0.2 to 0.5 w / v%, and particularly preferably 0.3 to 0.5 w / v%. The content of epsilon aminocaproic acid is not limited as long as the effects of the present disclosure are obtained. However, the content is preferably 5 to 1,000 parts by mass, more preferably 10 to 800 parts by mass, even more preferably 15 to 700 parts by mass, and particularly preferably 30 to 600 parts by mass per part by mass of the total content (total amount) of at least one selected from the group consisting of flavin adenine dinucleotide and salts thereof in the eyewash composition.

[0013] The eyewash composition does not contain a preservative selected from quaternary ammonium salt-based preservatives, parahydroxybenzoates, chlorobutanol, and sorbic acids. The preservatives are preservatives conventionally known in the fields of eye drops and eyewashes. Examples of quaternary ammonium-based preservatives include benzalkonium chloride and benzethonium chloride. Examples of parahydroxybenzoates include parahydroxybenzoates such as methyl parahydroxybenzoate, propyl parahydroxybenzoate, and butyl parahydroxybenzoate, as well as salts of parahydroxybenzoates (e.g., alkali metal salts such as sodium salts). Examples of sorbic acids include sorbic acid and salts of sorbic acid (e.g., alkali metal salts such as sodium salts and potassium salts, and alkaline earth metal salts such as calcium salts and magnesium salts).

[0014] The eyewash composition may further contain cyanocobalamin. When cyanocobalamin is contained, its content in the composition is not limited, but is preferably 0.0002 to 0.005 w / v%, more preferably 0.0005 to 0.003 w / v%, and even more preferably 0.001 to 0.003 w / v%. The content of cyanocobalamin in the composition is not limited as long as the effects of the present disclosure are obtained, but is preferably 0.01 to 5 parts by mass, more preferably 0.05 to 3 parts by mass, and even more preferably 0.1 to 1 part by mass per part by mass of the content (total amount) of at least one selected from the group consisting of flavin adenine dinucleotide and salts thereof in the composition.

[0015] The eyewash composition of the present disclosure may further contain any other component acceptable for use in eye drops or eyewashes. Examples of such other components include, but are not limited to, buffers, stabilizers, isotonicity agents, solvents, pH adjusters, thickeners, medicinal ingredients, and refreshing agents. The other components may be appropriately selected depending on the purpose, etc., as long as they do not impair the effects of the present disclosure. One type of other component may be used alone, or two or more types may be used in combination, and the amounts of these components may be appropriately determined.

[0016] Examples of such other components include buffers, such as boric acid and borax. A single buffer may be used, or two or more buffers may be used in combination. For example, when the composition contains boric acid, the content of boric acid in the composition is not limited as long as it does not impair the effects of the present disclosure, and is preferably 0.1 to 2.5 w / v%, more preferably 0.2 to 2 w / v%. For example, when the composition contains borax, the content of borax in the composition is not limited as long as it does not impair the effects of the present disclosure, and is preferably 0.005 to 0.5 w / v%, more preferably 0.001 to 0.1 w / v%. The composition may or may not contain a buffer other than boric acid or borax.

[0017] Examples of such other components include stabilizers, such as polysorbates (polysorbate 80, polysorbate 60, etc.), polyoxyethylene (POE) hydrogenated castor oil (POE(80) hydrogenated castor oil, POE(60) hydrogenated castor oil, etc.; the number in parentheses indicates the average number of moles of ethylene oxide added), lecithin, and sodium edetate (including hydrate). These may be used alone or in combination of two or more. When the composition contains a stabilizer, the content of the stabilizer is not limited as long as it does not impede the effects of the present disclosure, and is preferably 0.001 to 0.5 w / v%, and more preferably 0.005 to 0.1 w / v%, of the composition. When the composition contains a stabilizer, it may contain, for example, only one or only two selected from polysorbate, polyoxyethylene hydrogenated castor oil, lecithin, and sodium edetate. Also, when the composition contains, for example, polysorbate, it can be prepared without blending polyoxyethylene hydrogenated castor oil, lecithin, and / or sodium edetate.

[0018] Examples of such other components include medicinal components such as amino acids, anti-inflammatory agents (anti-phlogistic agents), corneal surface protective agents, antihistamines, etc. These may be used alone or in combination of two or more.

[0019] Although not limiting the present disclosure, examples of amino acids include amino acids and salts thereof, such as glutamic acid and its salts (e.g., monosodium glutamate); and amino acid analogs, such as taurine. These may be used alone or in combination of two or more. The eyewash composition of the present disclosure can also be prepared without adding an amino acid and / or a salt thereof. The amino acid here refers to an amino acid that can be a structural unit of a protein and has both an amino group and a carboxyl group, and includes, for example, L-aspartic acid. The eyewash composition of the present disclosure can also be prepared without adding an amino acid analog.

[0020] Although not limiting the present disclosure, examples of anti-inflammatory agents include zinc sulfate, zinc lactate, glycyrrhizinic acid and its salts (dipotassium glycyrrhizinate, etc.). These may be used alone or in combination of two or more. Although not limiting the present disclosure, the eyewash composition of the present disclosure contains epsilon aminocaproic acid, and therefore can be prepared without blending zinc sulfate and / or zinc lactate, or glycyrrhizinic acid and / or its salts. Note that, although epsilon aminocaproic acid is known as an anti-inflammatory agent, this component is not included in the description of the medicinal ingredient in the present disclosure, and therefore, the content of the medicinal ingredient does not include the content of epsilon aminocaproic acid.

[0021] Although not limiting the present disclosure, examples of corneal surface layer protective agents include chondroitin sulfate and its salts, hyaluronic acid and its salts, etc., and preferred examples of salts include alkali metal salts such as sodium salts. These may be used alone or in combination of two or more. Although not limiting the present disclosure, examples of the molecular weight of chondroitin sulfate and its salts include a weight-average molecular weight of preferably about 5,000 to 45,000, more preferably about 15,000 to 30,000. The eyewash composition of the present disclosure can also be prepared without blending chondroitin sulfate and its salts and / or hyaluronic acid and its salts.

[0022] When the composition of the present disclosure contains a medicinal ingredient, the content of the medicinal ingredient is not limited as long as it does not impair the effects of the present disclosure, and is exemplified by a content of preferably 0.01 to 1 w / v%, more preferably 0.025 to 0.5 w / v%, and even more preferably 0.1 to 0.3 w / v% in the composition. Note that, although the aforementioned flavin adenine dinucleotide and its salts, epsilon aminocaproic acid, and cyanocobalamin are known as medicinal ingredients, these ingredients are not included in the description of medicinal ingredients in the present disclosure, and therefore the content of these ingredients is not included in the content of the medicinal ingredient.

[0023] When the eyewash composition of the present disclosure contains a freshening agent, examples of the freshening agent include menthol, camphor, borneol, etc. When the freshening agent exists in the d-, l-, or dl-isomer, it does not matter which is which. A single freshening agent may be used, or two or more may be used in combination. The content of the freshening agent is not limited as long as it does not impair the effects of the present disclosure, and is preferably 0.0001 to 0.05 w / v%, more preferably 0.002 to 0.01 w / v%, in the composition. The composition can also be prepared without blending a freshening agent.

[0024] The eyewash composition of the present disclosure can be produced by mixing at least one selected from the group consisting of flavin adenine dinucleotide and its salts, epsilon aminocaproic acid, and optionally cyanocobalamin, and other ingredients. The composition does not contain a preservative selected from the group consisting of quaternary ammonium salt-based preservatives, parahydroxybenzoates, chlorobutanol, and sorbic acids.

[0025] For this reason, one embodiment of the eyewash composition of the present disclosure is a composition containing (1) at least one selected from the group consisting of flavin adenine dinucleotide and its salts, (2) epsilon aminocaproic acid as essential components, optionally containing (3) cyanocobalamin, and optionally containing (4) at least one selected from the group consisting of buffers, stabilizers, isotonicity agents, solvents, pH adjusters, thickeners, medicinal ingredients, and cooling agents, and (5) no preservatives selected from quaternary ammonium salt preservatives, parahydroxybenzoates, chlorobutanol, and sorbic acids. Another example of this embodiment is a composition containing at least one selected from the group consisting of (1), (2), and (3) and (4). As shown in the examples below, another example of this embodiment is a composition that does not contain components commonly used as preservatives in the fields of eye drops and eyewashes.

[0026] The pH of the eyewash composition of the present disclosure is not limited as long as it is within a range usable as an eye drop or eyewash, but examples thereof include a pH of 5 to 8 at room temperature (24°C), and from the viewpoint of further suppressing discoloration of the composition, a pH of preferably 5.5 to 7, more preferably 5.5 to 6.5, even more preferably 5.5 to 6, and particularly preferably 5.5 to 5.8. The pH is measured using a tabletop pH meter F-52 (manufactured by Horiba, Ltd.).

[0027] The eyewash composition of the present disclosure is in a liquid form at room temperature, and its method of use is not limited as long as it can cleanse the eyes in a manner similar to that of conventionally known methods. It is typically used for eyewashing using an eyewash cup (eyecup) or by eyedrops. Therefore, the composition is contained in a container and is used by pouring it from the container into an eyewash cup, or by instilling it directly into the eyes from the container. The viscosity and osmotic pressure (osmotic pressure ratio) of the composition are not limited as long as it can be used in this manner.

[0028] The eyewash composition of the present disclosure may be used with or without contact lenses, regardless of whether they are hard or soft contact lenses.

[0029] The eyewash composition of the present disclosure is not limited as long as it can be used as described above. When used in an eyewash cup, it is usually contained in a conventionally known, general eyewash container (e.g., including a container body and a cap). The container may be a type in which the container body and the cap are separate or integrated, and may also have an inner stopper (inner lid), which may have a hole for pouring the eyewash composition into the eyewash cup. The volume of the container is also not limited, but from the viewpoint of ease of use, the volume is preferably 350 to 550 mL, and more preferably 400 to 550 mL, for example.

[0030] Eyewashing using an eyewash cup can be done according to standard procedures. For example, an appropriate amount of the eyewash composition of the present disclosure is poured from the container into the eyewash cup, for example, 4 to 6 mL per eye, and then the cup is pressed against the area around one eye to bring the eyewash composition in the cup into contact with the eye, followed by blinking several times. The number of times the composition is used per day is not limited, and may be, for example, 1 to 6 times, 2 to 6 times, 3 to 6 times, or the like per eye. The eyes can be washed in this manner.

[0031] Furthermore, when the eyewash composition of the present disclosure is used for eyewashing by instillation, the composition is typically contained in an eyedrop container for ease of use. The eyedrop container is not limited as long as it can contain the composition and be used to instill the composition into the eyes, and examples thereof include eyedrop containers (e.g., including a container body, an inner stopper (nozzle), and a cap) used for conventionally known eyedrops, drop-type eyewashes, etc. The eyedrop container may be any of a type in which the container body, inner stopper (nozzle), and cap are independent, a type in which at least two of the container body, inner stopper (nozzle), and cap are integrated, a type in which a hole is provided in the inner stopper (nozzle), and a type in which the inner stopper (nozzle) has no hole and a hole is opened in the inner stopper (nozzle) by tightening the cap when used, and the like.

[0032] The volume of the eye drop container is not limited, but from the viewpoint of ease of use, the volume is, for example, 8 to 20 mL, preferably 10 to 15 mL, and more preferably 12 to 14 mL. The volume may be appropriately determined taking into consideration whether the eye drop container is a multi-dose type or a unit-dose type.

[0033] Eyewashing by instillation involves instilling 3 to 8 drops of the eyewash composition of the present disclosure per eye at a time. While not limited thereto, preferably 4 to 8 drops of the composition are instilled per eye at a time, and from the viewpoint of more efficient eyewashing, more preferably 4 to 6 drops. The amount of each drop is also not limited, but is preferably 35 to 40 μL, more preferably 35 to 37 μL per drop. The number of times the composition is used per day is also not particularly limited, and may be, for example, 1 to 12 times, 2 to 8 times, or 3 to 6 times per eye per day. Eyes can be washed in this manner.

[0034] Thus, by incorporating epsilon aminocaproic acid into an eyewash composition containing at least one selected from the group consisting of flavin adenine dinucleotide and its salts, discoloration of at least one selected from the group consisting of flavin adenine dinucleotide and its salts can be suppressed. Furthermore, as shown in the examples below, when the eyewash composition further contains cyanocobalamin, discoloration tends to progress when epsilon aminocaproic acid is not incorporated. However, by using at least one selected from the group consisting of flavin adenine dinucleotide and its salts in combination with cyanocobalamin and epsilon aminocaproic acid, discoloration can be suppressed. Furthermore, when the composition further contains the aforementioned medicinal ingredients, useful effects based on the medicinal ingredients can also be provided.

[0035] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these examples.

[0036] Test Example 1 1-1. Preparation of eyewash composition and evaluation of anti-fading properties Each composition was prepared by mixing the components according to the blending ratios shown in Table 1 (Examples 1 to 6, Reference Example 1, Comparative Examples 1 and 2). The pH of each composition was measured immediately after production. The pH was measured at room temperature (24°C) using a tabletop pH meter F-52 (manufactured by Horiba, Ltd.). 500 mL of each composition obtained was placed in an eyewash container (Eibon AL d, manufactured by Kobayashi Pharmaceutical Co., Ltd.) and the lid was closed. Separately, 10 mL of each composition obtained was placed in a drop-type eyewash container (volume 13 mL, made of polyethylene terephthalate resin, multi-dose type, manufactured by Shinko Chemical Co., Ltd.) and the lid was closed. The obtained compositions were pale yellow to pale yellowish brown in color.

[0037] The containers containing the compositions thus obtained were placed in a manner that exposed each container to sunlight in the same way, and exposed to sunlight for 9 hours. Five expert panelists visually inspected the color fading and scored the degree of fading on a scale of 1 to 15 according to the following criteria: a higher score indicates greater inhibition of fading; a score of 6 or higher indicates an acceptable degree of fading for practical use. The evaluation results in the table are the average values ​​for each composition, rounded to the nearest whole number. <Evaluation criteria> 15: No fading is observed after exposure compared to immediately after production. 10: Slight discoloration is observed after exposure compared to immediately after production, but is within the acceptable range. 5: Discoloration after exposure is observed compared to immediately after manufacture and is unacceptable. 1: Compared to immediately after production, the color faded significantly after exposure, becoming almost colorless.

[0038] 1-2.Results The results are shown in Table 1. In conducting this test, evaluation was performed according to the above criteria, and as shown in Table 1, the evaluation result for Reference Example 1 was 15, the evaluation result for Comparative Example 1 was 3, and the evaluation result for Example 4 was 6. Therefore, in the above evaluation, the degree of fading was evaluated in light of the degree of fading in these compositions in particular.

[0039] [Table 1]

[0040] Reference Example 1, which contained flavin adenine dinucleotide sodium (FAD) and the preservative methyl parahydroxybenzoate, received an evaluation result of 15, meaning no discoloration was observed. On the other hand, Comparative Example 1, which did not contain any preservatives as in Reference Example 1, received an evaluation result of 3, meaning discoloration that was unacceptable for a product was observed. Comparative Example 2, which increased the FAD content in Comparative Example 1, also failed to suppress the discoloration observed in Comparative Example 1.

[0041] In contrast, in Examples 1 to 6, in which epsilon aminocaproic acid was added in Comparative Example 1 or 2, the discoloration observed in Comparative Examples 1 and 2 was suppressed. This confirms that the use of epsilon aminocaproic acid in a composition containing FAD but not a preservative can suppress discoloration of FDA. Furthermore, discoloration could also be suppressed when the pH was changed to 7 in Example 6. Discoloration could also be suppressed when the pH was changed to 6 in Example 6, and in this case, the degree of discoloration suppression was even greater than in Example 6. It was also confirmed that discoloration could be suppressed in both the compositions contained in an eyewash container and in the compositions contained in a drop-type eyewash container.

[0042] Test Example 2 2-1. Preparation of eyewash compositions and evaluation of anti-fading properties The components were mixed according to the blending ratios shown in Table 2 below, and compositions were prepared so that the pH was 5.7 (Examples 7 to 10, Comparative Examples 3 and 4). The pH was measured in the same manner as in Test Example 1. Furthermore, in the same manner as in Test Example 1, each of the resulting compositions was placed in a container and evaluated for color fading. The resulting compositions were pale yellow to pale yellowish brown in color.

[0043] 2-2.Results The results are shown in Table 2.

[0044] [Table 2]

[0045] Examples 7 to 10 in Table 2 are compositions obtained by changing the pH of Examples 2, 3, 5, and 6 (pH 6.5) in Table 1 to 5.7, respectively. The compositions of Examples 7 to 10, which had a lower pH, were able to suppress discoloration more effectively than compositions such as Example 2. This confirms that the use of epsilon aminocaproic acid in a composition containing FAD but no preservative can suppress discoloration of FDA. It was also confirmed that discoloration of FDA can be suppressed even in compositions with a pH lower than the aforementioned pH 6.5. Although not shown in the table, discoloration was also suppressed when the pH of Example 1 was changed to 5.7, and in this case, discoloration was suppressed even more effectively than in Example 1. Furthermore, when the pH of Example 10 was changed to 5.5, discoloration was suppressed to the same extent as in Example 10. It was also confirmed that discoloration could be suppressed in both the compositions packaged in an eyewash container and in a drop-type eyewash container.

[0046] Test Example 3 3-1. Preparation of eyewash composition and evaluation of anti-fading properties The components were mixed according to the blending ratios shown in Table 3 below, and compositions were prepared so that the pH was 5.7 (Examples 11 and 12, Reference Example 2, Comparative Example 5). The pH was measured in the same manner as in Test Example 1. Furthermore, in the same manner as in Test Example 1, each of the resulting compositions was placed in a container and evaluated for color fading. Each of the resulting compositions exhibited a light yellowish brown to light orange color.

[0047] 3-2.Results The results are shown in Table 3.

[0048] [Table 3]

[0049] Comparative Example 5 is a composition in which cyanocobalamin was further added to the composition of Comparative Example 4, and the composition of Comparative Example 5 containing cyanocobalamin faded more than the composition of Comparative Example 4 which did not contain cyanocobalamin. This indicates that the addition of cyanocobalamin further accelerates fading.

[0050] In Reference Example 2, in which methyl parahydroxybenzoate (a preservative) was added in Comparative Example 5, the evaluation result was 15, and the discoloration observed in Comparative Example 5 was no longer observed. Furthermore, in Examples 11 and 12, in which epsilon aminocaproic acid was added in Comparative Example 5, the discoloration observed in Comparative Example 5 was significantly suppressed. This confirms that the use of epsilon aminocaproic acid in a composition containing FAD and cyanocobalamin but no preservative can suppress discoloration. Furthermore, although discoloration is accelerated when a composition containing FAD further contains cyanocobalamin, the incorporation of epsilon aminocaproic acid significantly improves discoloration. It was also confirmed that discoloration can be suppressed in both the compositions contained in an eyewash container and in a drop-type eyewash container.

[0051] Prescription example Table 4 shows formulation examples of eyewash compositions of the present disclosure. The formulation examples shown in Table 4 were also evaluated for discoloration in the same manner as in Test Example 1. It was confirmed that formulation examples 1 to 8 could suppress discoloration compared to compositions not containing epsilon-aminocaproic acid.

[0052] [Table 4]

Claims

1. Contains at least one selected from the group consisting of flavin adenine dinucleotide and salts thereof, and epsilon aminocaproic acid; the content of at least one selected from the group consisting of flavin adenine dinucleotide and salts thereof is 0.001 to 0.005 w / v %, the content (total amount) of epsilon aminocaproic acid is 50 to 500 parts by mass per part by mass of at least one selected from the group consisting of flavin adenine dinucleotide and salts thereof, does not contain a preservative selected from quaternary ammonium salt-based preservatives, parahydroxybenzoic acid esters, chlorobutanol, and sorbic acids; Eyewash composition (However, this does not include eyewash compositions containing carboxyvinyl polymers.)

2. 2. The eyewash composition of claim 1, further comprising cyanocobalamin.

3. The eyewash composition according to claim 1 or 2, which is used for eyewash using an eyewash cup or for eyewash by eye drops.

Images